

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## EQUALITY IMPACT ASSESSMENT

### NICE guidelines

#### Chronic obstructive pulmonary disease in over 16s (triple therapy addendum 2019)

##### 4.0 Final guideline (to be completed by the Developer before GE consideration of final guideline)

4.1 Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed them?

No additional issues were raised during consultation.

4.2 If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The recommendations have been changed slightly to include more details about issues to consider during the clinical review prior to starting triple therapy and the 3 month trial period. These changes are not expected to disadvantage any particular groups of people.

4.3 If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

The changes to the recommendations are not expected to have this effect.

4.4 If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in question 4.2, or otherwise fulfil NICE's obligations to advance equality?

The changed recommendations are not expected to introduce any barriers to, or difficulties with, access to services.

4.5 Have the Committee's considerations of equality issues been described in the final guideline, and, if so, where?

In general, the Committee's considerations of equality issues are described in the evidence reviews for each question, in particular in the benefits and harms, and other considerations sections of the discussion sections associated with the relevant review questions. However, since no new equality issues were identified for the current update the 2019 chapters do not contain any discussion of equalities issues. Please refer to section 3.1 for details of how the committee addressed equalities issues and see the discussion sections of the 2018 inhaled therapy evidence review for considerations regarding equality issues that are also relevant to the current triple therapy review.

Updated by Developer: Susan Spiers

Date 15/05/2019

Approved by NICE quality assurance lead: Simon Ellis

Date: 13/06/2019